These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27323416)

  • 1. Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy.
    Wan X; Pu H; Huang W; Yang S; Zhang Y; Kong Z; Yang Z; Zhao P; Li A; Li T; Li Y
    Oncotarget; 2016 Aug; 7(32):51284-51300. PubMed ID: 27323416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2.
    Kroiss A; Vincent S; Decaussin-Petrucci M; Meugnier E; Viallet J; Ruffion A; Chalmel F; Samarut J; Allioli N
    Oncogene; 2015 May; 34(22):2846-55. PubMed ID: 25065599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
    Wan X; Huang W; Yang S; Zhang Y; Zhang P; Kong Z; Li T; Wu H; Jing F; Li Y
    Int J Biochem Cell Biol; 2016 Oct; 79():249-260. PubMed ID: 27594411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
    Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
    Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A
    Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
    Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
    Gui B; Hsieh CL; Kantoff PW; Kibel AS; Jia L
    PLoS One; 2017; 12(9):e0184166. PubMed ID: 28886115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
    Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
    O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
    Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.
    Zennami K; Choi SM; Liao R; Li Y; Dinalankara W; Marchionni L; Rafiqi FH; Kurozumi A; Hatano K; Lupold SE
    Mol Cancer Res; 2019 Feb; 17(2):618-627. PubMed ID: 30518628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
    Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
    Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
    Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
    World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis.
    Zhang Y; Zhao J; Ding M; Su Y; Cui D; Jiang C; Zhao S; Jia G; Wang X; Ruan Y; Jing Y; Xia S; Han B
    J Exp Clin Cancer Res; 2020 Dec; 39(1):282. PubMed ID: 33317606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lncRNA PTTG3P promotes the progression of CRPC via upregulating PTTG1.
    Huang S; Liao Q; Li W; Deng G; Jia M; Fang Q; Ji H; Meng M
    Bull Cancer; 2021 Apr; 108(4):359-368. PubMed ID: 33743960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.